Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial conducted in the USA
Gastroenterology 74(6):12241228
All authors read and approved the final version of the manuscript
However, due to concerns for safety, quality, and effectiveness of compounded GLP1RAs, the American Diabetes Association (ADA) has issued guidance recommending switching individuals to different FDA-approved medications to achieve and maintain individualized glucose-lowering, weight management, and/or cardiovascular and kidney risk reduction goals when supply or access is limited [75]